Transplant conditioning with mobilization and alemtuzumab (DrugBank: Alemtuzumab)
21 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
13 | Multiple sclerosis/Neuromyelitis optica | 0 |
15 | Inclusion body myositis | 0 |
19 | Lysosomal storage disease | 0 |
20 | Adrenoleukodystrophy | 0 |
43 | Microscopic polyangiitis | 0 |
44 | Wegener granulomatosis | 0 |
46 | Malignant rheumatoid arthritis | 0 |
49 | Systemic lupus erythematosus | 0 |
51 | Scleroderma | 0 |
60 | Aplastic anemia | 0 |
62 | Paroxysmal nocturnal hemoglobinuria | 0 |
63 | Idiopathic thrombocytopenic purpura | 0 |
65 | Primary immunodeficiency | 1 |
85 | Idiopathic interstitial pneumonia | 0 |
96 | Crohn disease | 0 |
164 | Oculocutaneous albinism | 0 |
234 | Peroxisomal disease (except Adrenoleukodystrophy) | 0 |
283 | Acquired pure red cell aplasia | 0 |
284 | Diamond-Blackfan anemia | 0 |
285 | Fanconi anemia | 0 |
326 | Osteopetrosis | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01182675 (ClinicalTrials.gov) | August 2010 | 9/8/2010 | Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim | Hematopoietic Stem Cell Transplantation for Children With Severe Combined Immunodeficiency Disease Utilizing Alemtuzumab and Mobilization With Plerixafor & Filgrastim | Severe Combined Immunodeficiency | Drug: Transplant Conditioning with Mobilization Only;Drug: Transplant Conditioning with Mobilization and Alemtuzumab | University of California, San Francisco | NULL | Terminated | N/A | 3 Years | All | 7 | Phase 2 | United States |